ISRCTN ISRCTN98404761
DOI https://doi.org/10.1186/ISRCTN98404761
Protocol serial number ICU-FM-I-2016-1-1-2
Sponsor UZ Leuven
Funders KU Leuven, Flanders Government FWO
Submission date
03/05/2017
Registration date
17/05/2017
Last edited
26/05/2020
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Signs and Symptoms
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Critical illness is a state in which patients depend on drugs or machines to support or replace organ function to keep them alive and allow them to heal. Such patients are admitted to intensive care units (ICU) to receive care. Critically ill patients are at risk of losing muscle power due to due to the natural breakdown of tissue from inactivity. Short term fasting may be beneficial in the recovery of disease. Even in ICU, withholding intravenous nutrition (nutrition delivered through a drip) for one week, surprisingly, avoids complications and allows severely ill patients to recover faster and go home earlier. This study is aiming to see if these beneficial effects can be broadened beyond the first week of critical illness. The aim of this study is to design a new fasting mimicking diet in ICU (ICU-FM) based on cyclic feeding interruptions and look at its effects.

Who can participate?
Adult patients in ICU who are unable to eat by mouth.

What does the study involve?
Participants are randomly allocated to undergo 12 hours of receiving nutrition through a drip or straight into the gut followed by 12 hours of fasting, or 12 hours of fasting followed by 12 hours of receiving nutrition through a drip or straight into the gut. If the 12 hour time period is judged to be insufficient, then the process is repeated using 24 hour time periods. At the start of the study and then after 12 or 24 hours (depending on the time period used), participants have samples of blood collected to assess their health. In addition, participants have their medical records reviewed after 7 and 90 days to assess survival rates.

What are the possible benefits and risks of participating?
There are no direct benefits or risks involved with participating.

Where is the study run from?
UZ Leuven (Belgium)

When is the study starting and how long is it expected to run for?
June 2016 to October 2017

Who is funding the study?
1. KU Leuven (Belgium)
2. Flanders Government FWO (Belgium)

Who is the main contact?
Dr Michael P. Casaer
michael.casaer@uzleuven.be

Contact information

Prof Michael P. Casaer
Scientific

Clincial Department of Intensive Care Medicine
UZ Leuven
Herestraat 49
Leuven
3000
Belgium

ORCiD logoORCID ID 0000-0002-7087-0795
Phone +32 16 34 87 86
Email michael.casaer@uzleuven.be

Study information

Primary study designInterventional
Study designPilot randomised cross-over study
Secondary study designRandomised cross over trial
Study type Participant information sheet
Scientific titleICU-FM: Implementation into the intensive care unit (ICU) of the beneficial effects of fasting (mimicking diets) (FM)
Study acronymICU-FM-I
Study objectivesTwelve hours of nutrient restriction are sufficient to provoke a metabolic fasting response in critically ill patients, as reflected by increased plasma bilirubin and decreased insulin requirements.
Ethics approval(s)Commissie Medische Ethiek UZ KU Leuven , 27/07/2016, ref: B322201629914
Health condition(s) or problem(s) studiedProlonged critical illness
InterventionParticipants are randomised by central computer in permuted blocks (size unknown to all involved) in a 1:1 ratio to either the 12/12 (or 24/24 if 12 hours would be not sufficient) caloric restriction (CR) regime followed by feeding or feeding followed by CR. All outcome assessors will be blinded for treatment allocation.

Nutritional targets will be achieved by EN±PN, as appropriate with a full feeding target of 20-25 kcal/kg ideal body weight, a dosage defined by age (< or > 60 years) and gender. During fasting intervals, no nutrition will be administered, unless spontaneous hypoglycemia occurs. The intervention is thus to infuse enteral and/or parenteral nutrition as required to achieve nutritional target during a 12 hours (or in faze 2: 24 hours) interval on ICU day 8. This is followed by a 12 hours or 24 hours fasting. The sequence of this metabolic cross over experiment is determined by randomization.

Plasma bilirubin, creatinine, BUN and glucose values and insulin requirements will be collected at study start, after the fasting window and after full feeding. Blood samples for evaluation of other changes in metabolism and cellular biology will be drawn likewise before and after the feeding and fasting interval.
Intervention typeOther
Primary outcome measure(s)

1. Plasma bilirubin is measured by colorimetric assay in the Laboratory of Intensive Care Medicine at baseline and after the first and second intervention time window (12 hours or 24 hours according to the study phase)
2. Insulin requirements (total dose delivered over intervention time interval, this is the last 12 hours or 24 hours according to the study phase) are measured by reviewing the ICU-PDMS (Patient Data Management System [Metavision]) at baseline and after the first and the second intervention time window (this is after 12 hours and 24 hours in the first phase and eventually after 24 hours and 48 hours in the second phase of the study)

Key secondary outcome measure(s)

1. Mortality is measured using data from the National Registry via Hospital Clinical Work Station (KWS) at 90 days
2. New ICU-Morbidity occurring in the first week after randomization is assessed by reviewing the ICU-PDMS (Patient Data Management System [Metavision]) at baseline and 7 days

Completion date01/10/2017

Eligibility

Participant type(s)Patient
Age groupAdult
SexAll
Target sample size at registration70
Total final enrolment70
Key inclusion criteria1. Adult ICU-patients
2. Unable to eat by mouth
3. Expected on day 7 to stay 3 more days in ICU
Key exclusion criteria1. Patients with severe jaundice
2. Bilirubin > 5mg/dL, pregnant
3. Lactating patients
Date of first enrolment01/06/2017
Date of final enrolment01/10/2017

Locations

Countries of recruitment

  • Belgium

Study participating centre

UZ Leuven
Clincial Department of Intensive Care Medicine
Herestraat 49
Leuven
3000
Belgium

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot expected to be made available
IPD sharing planThe participant level data of this step I pilot metabolic cross over clinical experiment will not be publicly available. This would be a potential source of erroneous findings due to inadequate interpretation of the study design. The data will be stored in the research database of the Clinical Department and Laboratory of Intensive Care Medicine and request for post-hoc analyses with a clearly defined research question and methodology can be sent to the investigators. This approach to avoid misinterpretation of complex data and databases has been proposed in a recent summit on data-sharing organized by the NEJM in April 2017.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 24/05/2020 26/05/2020 Yes No
Participant information sheet Participant information sheet 11/11/2025 11/11/2025 No Yes
Study website Study website 11/11/2025 11/11/2025 No Yes

Editorial Notes

26/05/2020: The following changes were made to the trial record:
1. Publication reference added.
2. The total final enrolment was added.
22/09/2017: Internal review.